Thursday, October 08, 2020 3:42:50 PM
The World Health Organization has finally confirmed what we (and many experts and studies) have been saying for months – the coronavirus is no more deadly or dangerous than seasonal flu.
The WHO’s top brass made this announcement during a special session of the WHO’s 34-member executive board on Monday October 5th, it’s just nobody seemed to really understand it.
In fact, they didn’t seem to completely understand it themselves.
At the session, Dr Michael Ryan, the WHO’s Head of Emergencies revealed that they believe roughly 10% of the world has been infected with Sars-Cov-2. This is their “best estimate”, and a huge increase over the number of officially recognised cases (around 35 million).
Dr. Margaret Harris, a WHO spokeswoman, later confirmed the figure, stating it was based on the average results of all the broad seroprevalence studies done around the world.
As much as the WHO were attempting to spin this as a bad thing – Dr Ryan even said it means “the vast majority of the world remains at risk.” – it’s actually good news. And confirms, once more, that the virus is nothing like as deadly as everyone predicted.
The global population is roughly 7.8 billion people, if 10% have been infected that is 780 million cases. The global death toll currently attributed to Sars-Cov-2 infections is 1,061,539.
That’s an infection fatality rate of roughly or 0.14%. Right in line with seasonal flu and the predictions of many experts from all around the world.
0.14% is over 24 times LOWER than the WHO’s “provisional figure” of 3.4% back in March. This figure was used in the models which were used to justify lockdowns and other draconian policies.
In fact, given the over-reporting of alleged Covid deaths, the IFR is likely even lower than 0.14%, and could show Covid to be much less dangerous than flu.
None of the mainstream press picked up on this. Though many outlets reported Dr Ryan’s words, they all attempted to make it a scary headline and spread more panic.
Apparently neither they, nor the WHO, were capable of doing the simple maths that shows us this is good news. And that the Covid sceptics have been right all along.
https://off-guardian.org/2020/10/08/who-accidentally-confirms-covid-is-no-more-dangerous-than-flu/
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
